JP Morgan Maintains Overweight on Intellia Therapeutics, Lowers Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng maintains an Overweight rating on Intellia Therapeutics (NASDAQ:NTLA) but lowers the price target from $61 to $55.
August 12, 2024 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Brian Cheng maintains an Overweight rating on Intellia Therapeutics but lowers the price target from $61 to $55.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100